Compare Google Inc (GOOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs BIO-TECHNE Corp — how do they compare? Google Inc trades at $343 (market cap $4.36T), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Google Inc is far larger — about 387.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| GOOG | TECH | |
|---|---|---|
Market Cap | $4.36T | $11.24B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $72.29 |
52-Week Low | $200.19 | $43.31 |
Enterprise Value | $4.25T | $11.32B |
Dividend Yield | 0.25% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $353.47, down 0.88% today, with a bullish technical outlook supported by moving averages and strong support at $352. The company shows robust fundamentals, with 2025 revenue of $402.84B and net income of $132.17B, alongside consecutive earnings beats in recent quarters. Recent news highlights aggressive AI investments and cloud growth, while analyst sentiment remains overwhelmingly positive.
The outlook for GOOG is favorable, driven by AI expansion and cloud revenue growth, with a consensus price target of $431.67 implying significant upside. Risks include high capital expenditures, competitive pressures, and regulatory scrutiny, but strong cash flow and profitability metrics support a bullish investment case for long-term investors.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
